Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New syrup aims to soothe coughs in just two days

NCT ID NCT07625683

Symptom relief Sponsor: Laboratoires Elerte Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well and how safely SIROPSEDAL syrup works for acute cough caused by colds or upper respiratory infections. About 124 children and adults will take the syrup as prescribed by their doctor and report their cough severity over one week. The main goal is to see if most people feel a meaningful reduction in cough by the second day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SIROPSEDAL (a syrup for cough)
What this could lead to
If it works, this could confirm that SIROPSEDAL effectively reduces cough intensity within two days for people with acute cough from colds or respiratory infections.
What could go wrong
This is an observational study without a placebo group, so results may be less reliable. It is also small (124 people) and only follows participants for one week, so long-term effects or comparisons to other treatments are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children and adults from 1 year of age presenting with acute cough for less than 10 days in French general practice, for whom SIROPSEDAL has been prescribed in routine care independently of study participation.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than or equal to 1 year. * Acute cough evolving for less than 10 days. * Cough intensity VAS greater than 40/100. * SIROPSEDAL prescribed independently from study participation. * No hospitalization required. * Written informed consent from the patient or from parent(s)/legal representative for minors, as applicable. * Able to attend the Day 7 +/- 1 day visit or teleconsultation. * Affiliated with or beneficiary of a health insurance system. Exclusion Criteria: * ACE inhibitor or sartan use. * Asthma or COPD. * Corticosteroids ongoing or within the previous 3 days. * Antibiotics ongoing or within the previous 3 days. * Antitussives ongoing or within the previous 3 days. * Antihistamines ongoing or within the previous 3 days. * Aerosol therapy ongoing or within the previous 3 days. * Severe signs suggesting a causal disease requiring additional investigations according to the investigator. * Severe signs requiring corticosteroids, aerosol therapy or centrally acting antitussive treatment according to the investigator. * Any contraindication listed in the instructions for use. * Patient under legal protection. * Pregnancy. * Intolerance, hypersensitivity or allergy to one or more product components.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute cough are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common cold Cough respiratory tract infectious disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute cough Common cold Upper respiratory tract infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Multiples facilities

    Multiple Locations, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.